EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 is a nanomolar-range DOT1L inhibitor developed for precise epigenetic regulation in cancer research (APExBIO product dossier). It demonstrates >37,000-fold selectivity over other methyltransferases, ensuring minimal off-target effects. In MLL-rearranged leukemia models, EPZ5676 inhibits H3K79 methylation and induces potent cytotoxicity. In vivo, it drives complete tumor regression in MV4-11 xenograft-bearing rats with no significant toxicity. Its robust biochemical and pharmacological profile makes it a reference tool for histone methyltransferase inhibition assays (Anichini et al., 2022).

Biological Rationale

Epigenetic dysregulation is a hallmark of many cancers, including acute leukemias with mixed lineage leukemia (MLL) gene rearrangements. DOT1L, a histone methyltransferase, catalyzes methylation of lysine 79 on histone H3 (H3K79). This modification is essential for normal gene expression and chromatin structure. Aberrant recruitment of DOT1L by MLL fusion proteins drives oncogenic gene expression programs, making DOT1L a validated therapeutic target in MLL-rearranged leukemia (Anichini et al., 2022). Selective inhibition of DOT1L disrupts these pathways without broadly affecting other methyltransferases, minimizing systemic toxicity. EPZ5676, supplied by APExBIO, is engineered to exploit this vulnerability with high specificity (APExBIO).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a competitive inhibitor of DOT1L, targeting the enzyme's S-adenosyl methionine (SAM) binding pocket. By occupying this site, EPZ5676 induces a conformational change that expands a hydrophobic pocket beyond the native SAM binding region. This structural alteration blocks methyltransferase activity, specifically inhibiting H3K79 methylation. The IC₅₀ for DOT1L is 0.8 nM, with a K_i of 80 pM, indicating exceptionally high potency. Selectivity profiling reveals >37,000-fold discrimination against other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. This selectivity is critical for clean interrogation of DOT1L-dependent pathways in cellular and animal models (APExBIO).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L with an IC₅₀ of 0.8 nM and K_i of 80 pM under standard enzymatic assay conditions (APExBIO, product page).
• Demonstrates >37,000-fold selectivity for DOT1L over 12 other methyltransferases, including EZH2, G9a, and PRMT5 (APExBIO, product page).
• Inhibits H3K79 methylation and downregulates MLL-fusion target gene expression in MLL-rearranged leukemia cells (Anichini et al., 2022, DOI).
• Shows potent cytotoxicity in MV4-11 (MLL-AF4) acute leukemia cell lines with an IC₅₀ of 3.5 nM (4–7 days treatment, RPMI 1640, 37°C, 5% CO₂) (APExBIO).
• In vivo, EPZ5676 (35–70 mg/kg/day IV, 21 days) leads to complete tumor regression in MV4-11 xenograft-bearing nude rats, with no significant toxicity or weight loss (APExBIO).
• EPZ5676 is insoluble in water, but soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (ultrasonic assistance) (APExBIO, product page).
• Robust epigenetic modulation by DOT1L inhibition is confirmed in multiple studies, augmenting immunomodulatory effects in cancer models (Anichini et al., 2022, DOI).

This article extends the mechanistic detail provided in "EPZ5676: Potent and Selective DOT1L Inhibitor for Epigene..." by including recent in vivo efficacy data and practical workflow parameters. For a discussion on immune signaling reprogramming, see "EPZ5676: Advancing DOT1L Inhibition for Immune Reprogramm...", while this piece offers an updated biochemical selectivity profile.

Applications, Limits & Misconceptions

EPZ5676 has validated applications in:

• Biochemical DOT1L enzyme inhibition assays using purified recombinant proteins.
• Cell proliferation and viability studies in acute leukemia models, especially MLL-rearranged subtypes.
• In vivo efficacy assessment in xenograft models of leukemia.
• Advanced epigenetic modulation workflows targeting H3K79 methylation.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective in cancers lacking DOT1L dependency: It does not impact cell lines or tumors without DOT1L-driven oncogenic pathways.
• Not a broad-spectrum methyltransferase inhibitor: EPZ5676 exhibits negligible activity against other histone methyltransferases, including EZH2 and PRMT5.
• Insoluble in aqueous buffers: EPZ5676 must be dissolved in DMSO or ethanol; water-based solutions are unsuitable.
• Not intended for chronic in vivo administration without pharmacokinetic optimization: Current data supports short-term, high-dose regimens in preclinical models only.
• Does not replace genetic DOT1L knockout: Chemical inhibition is reversible and context-dependent, unlike permanent gene editing.

Workflow Integration & Parameters

EPZ5676 is supplied as a solid (molecular weight: 562.71 g/mol) by APExBIO. Stock solutions can be prepared at ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol (with ultrasonic assistance). It is insoluble in water. Store powder at -20°C and avoid repeated freeze-thaw cycles of solutions. For enzyme inhibition assays, typical working concentrations range from 0.1 to 10 nM. For cell-based assays, treat MV4-11 cells with 3–10 nM EPZ5676 for 4–7 days. In vivo studies employ 35–70 mg/kg/day administered intravenously for up to 21 days. Solutions in DMSO are stable for several months below -20°C. Always reference the latest APExBIO protocols for optimized assay conditions (see DOT1L inhibitor EPZ-5676).

Conclusion & Outlook

EPZ5676 remains the reference DOT1L inhibitor for targeted epigenetic modulation in MLL-rearranged leukemia research. Its unmatched selectivity, robust in vitro and in vivo efficacy, and well-characterized biochemical profile support its adoption in both discovery and translational workflows. As epigenetic therapy evolves to include immunomodulatory strategies, precise inhibitors like EPZ5676 are poised to play a central role in combinatorial regimens (Anichini et al., 2022). For detailed product information and protocols, consult the APExBIO DOT1L inhibitor EPZ-5676 (A4166) page.